Cutting Edge: Novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus

Natasa Strbo, Monica Vaccari, Savita Pahwa, Michael A. Kolber, Melvin N. Doster, Eva Fisher, Louis Gonzalez, Donald Stablein, Genoveffa Franchini, Eckhard R. Podack

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

Vaccine-induced protection against infection by HIV or highly pathogenic and virulent SIV strains has been limited. In a proof-of-concept study, we show that a novel vaccine approach significantly protects rhesus macaques from mucosal infection by the highly pathogenic strain SIVmac251. We vaccinated three cohorts of 12 macaques each with live, irradiated vaccine cells secreting the modified endoplasmic reticulum chaperone gp96-Ig. Cohort 1 was vaccinated with cells secreting gp96SIVIg carrying SIV peptides. In addition, Cohort 2 received recombinant envelope protein SIV-gp120. Cohort 3 was injected with cells secreting gp96-Ig (no SIV Ags) vaccines. Cohort 2 was protected from infection. After seven rectal challenges with highly pathogenic SIVmac251, the hazard ratio was 0.27, corresponding to a highly significant, 73% reduced risk for viral acquisition. The apparent success of the novel vaccine modality recommends further study.

Original languageEnglish (US)
Pages (from-to)2495-2499
Number of pages5
JournalJournal of Immunology
Volume190
Issue number6
DOIs
StatePublished - Mar 15 2013

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Cutting Edge: Novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus'. Together they form a unique fingerprint.

Cite this